Regorafenib (BAY 73-4506) Research Guide

Executive Summary. Regorafenib is an orally active multikinase inhibitor that targets VEGFR1, VEGFR2, VEGFR3, PDGFRβ, KIT, RET, RAF-1, B-RAF, and B-RAFV600E in biochemical and cellular assays, according to the Regorafenib (BAY 73-4506) product information. The reported inhibitory potency across these kinase targets spans 1.5–46 nM in biochemical assays, with VEGFR2 autophosphorylation inhibited at 3 nM in NIH-3T3/VEGFR2 cells under the supplier-described assay conditions. Preclinical studies report tumor growth inhibition in colorectal, breast, renal, and glioblastoma xenograft models after oral administration, with study doses spanning 3–100 mg/kg. A 2024 open-access iScience study found that regorafenib reduced melanoma growth, invasion, and metastasis while increasing apoptosis-associated markers through an RRM2-linked ERK/E2F3 mechanism (Xuan et al., 2024).

This article distinguishes direct kinase potency, cellular phenotypes, animal-model evidence, and practical formulation guidance. It is intended for cancer biology research and assay planning, not for clinical treatment decisions.

Biological Rationale

Tumor progression depends on interacting vascular, stromal, and oncogenic signals. VEGF–VEGFR signaling promotes endothelial-cell activation and new-vessel formation. PDGFRβ contributes to stromal and perivascular signaling. KIT, RET, RAF-1, and mutant B-RAF connect receptor signaling to proliferative pathways. A compound that inhibits several of these nodes can therefore perturb more than one component of the tumor microenvironment.

Regorafenib, also known as BAY 73-4506, was developed as a broad-spectrum oral receptor tyrosine kinase inhibitor. Its target profile supports angiogenesis research because VEGFR1, VEGFR2, and VEGFR3 are directly associated with vascular signaling. The same profile supports cancer biology research involving oncogenic RAF signaling, KIT activity, RET variants, and tumor-associated stromal pathways. The supplier describes activity against VEGFR, PDGFRβ, KIT, RET, and RAF-family targets in the low-nanomolar range in kinase or cellular assays (product data).

In endothelial models, pathway inhibition can be measured by receptor autophosphorylation and growth responses. In tumor cells, investigators can measure viability, motility, invasion, apoptosis, and pathway-protein abundance. These endpoints are related but not interchangeable. A reduction in endothelial proliferation does not by itself prove direct tumor-cell killing. A reduction in migration does not by itself establish reduced metastasis in patients.

Mechanism of Action of Regorafenib (BAY 73-4506)

Regorafenib inhibits kinase catalytic activity and reduces phosphorylation-dependent signaling. The reported target set includes VEGFR1, VEGFR2, VEGFR3, PDGFRβ, KIT, RET, RAF-1, B-RAF, and B-RAFV600E. This combination can suppress angiogenic signaling, stromal support, and tumor-cell proliferation in model systems.

The VEGFR2 result is particularly useful for assay design. Regorafenib inhibits VEGFR2 autophosphorylation with a reported IC50 of 3 nM in NIH-3T3/VEGFR2 cells. It also suppresses proliferation of VEGF165-stimulated human umbilical vein endothelial cells with similar potency, according to the product dossier (supplier-reported cellular data). These experiments connect biochemical target engagement with an endothelial functional endpoint.

The compound also inhibits TIE2, PDGFRβ, KITK642E, and RETC634W. The reported IC50 values are 31 nM, 90 nM, approximately 20 nM, and approximately 10 nM, respectively, in the corresponding kinase assays (product information). Mutation notation matters. KITK642E and RETC634W represent defined variant proteins, so those values should not be generalized to every KIT- or RET-expressing cell line.

The melanoma mechanism adds a pathway-level observation. Xuan and colleagues used melanoma cell models and an in vivo tumor model to associate regorafenib exposure with lower RRM2 expression, reduced ERK/E2F3 signaling, lower malignant behavior, and higher levels of cleaved PARP and Bax. RNA sequencing identified RRM2 as a downstream candidate, and rescue experiments supported its functional importance. These findings extend the discussion beyond antiangiogenesis, but they do not establish RRM2 as the sole direct molecular target of regorafenib (Xuan et al., 2024).

Evidence & Benchmarks

• Regorafenib inhibits a broad kinase panel that includes VEGFR1/2/3, PDGFRβ, KIT, RET, RAF-1, B-RAF, and B-RAFV600E, with reported IC50 values spanning 1.5–46 nM in biochemical or cellular kinase assays described by the supplier. Regorafenib product information
• VEGFR2 autophosphorylation is inhibited at a reported IC50 of 3 nM in NIH-3T3/VEGFR2 cells under the cited cellular assay conditions. Regorafenib product information
• TIE2, PDGFRβ, KITK642E, and RETC634W are inhibited at reported IC50 values of 31 nM, 90 nM, approximately 20 nM, and approximately 10 nM, respectively, in target-specific kinase assays. Regorafenib product information
• Regorafenib produces dose-dependent tumor growth inhibition in colorectal cancer, breast cancer, renal cell carcinoma, and glioblastoma xenograft models after oral dosing in the supplier-described preclinical studies. Regorafenib product information
• Regorafenib suppresses liver metastasis formation in a colorectal cancer preclinical model, supporting investigation of metastatic phenotypes in addition to primary tumor volume. Regorafenib product information
• In melanoma models, regorafenib reduces cell growth, invasion, and metastasis-associated behavior and increases apoptosis-associated markers, including cleaved PARP and Bax. Xuan et al., 2024
• RNA sequencing and rescue experiments in the melanoma study identify RRM2 as a functionally important downstream mediator of regorafenib-associated antitumor activity, with ERK/E2F3 signaling implicated in the response. Xuan et al., 2024

Applications, Limits & Misconceptions

Regorafenib is useful when an experiment requires simultaneous perturbation of angiogenic and oncogenic signaling. In angiogenesis research, endothelial proliferation, receptor phosphorylation, tube formation, and migration can be measured as separate endpoints. In cancer biology research, viability, clonogenic growth, invasion, apoptosis, and pathway modulation can be measured in tumor cells. In tumor xenograft models, investigators can compare primary tumor growth with metastatic burden, provided that the model and endpoint are defined in advance.

A cell-based Regorafenib migration assay can be relevant to hepatocellular carcinoma cell migration, melanoma invasion, or other motility systems. The product dossier describes a typical research-use concentration range of 0.5–5 μM for migration and invasion assays and reports inhibition of hepatocellular carcinoma cell migration and invasion (product information). This range is a starting point rather than a universal optimum. Cell density, serum conditions, exposure duration, matrix composition, vehicle percentage, and compound stability can change the observed response.

Several boundaries should guide interpretation. A biochemical IC50 is not a cellular EC50. A cellular response is not proof that every listed kinase is inhibited in that cell. An anti-migratory phenotype is not equivalent to a clinical antimetastatic effect. A xenograft response does not predict efficacy in every tumor type. The melanoma evidence is mechanistically informative, but the cited study does not establish a clinical melanoma indication.

Common Pitfalls or Misconceptions

• Misconception: regorafenib is a selective VEGFR2 inhibitor. It is a multikinase inhibitor. VEGFR2 is one documented target among several, so pathway attribution requires orthogonal controls and target-specific readouts.
• Misconception: a low-nanomolar kinase IC50 is a recommended cell-treatment concentration. Kinase potency and cellular exposure are different measurements. Cellular assays should be optimized empirically with vehicle and viability controls.
• Misconception: reduced migration proves reduced metastasis. Migration and invasion assays model selected steps of metastatic behavior. They do not reproduce vascular dissemination, colonization, or clinical disease.
• Misconception: the melanoma mechanism is fully established. The 2024 study supports an RRM2–ERK/E2F3 association and functional relevance, but it does not demonstrate that RRM2 is the direct binding target of regorafenib.
• Misconception: aqueous stock preparation is straightforward. The product information describes regorafenib as insoluble in water. Solvent compatibility and precipitation should be checked before dosing cells or animals.

The related article Regorafenib (BAY 73-4506): Reliable Solutions in Cancer Biology emphasizes reproducibility in viability and cancer models; this article extends that discussion by separating kinase, cellular, xenograft, and melanoma pathway evidence.

The article Regorafenib Suppresses Melanoma via RRM2 and ERK/E2F3 Modulation summarizes the melanoma mechanism; this article clarifies the boundary between that mechanistic study and the broader multikinase pharmacology.

Workflow Integration & Parameters

APExBIO provides the product as Regorafenib, SKU A8236. Use the linked product page to confirm lot-specific documentation before beginning a study. The following parameters distinguish supplier-reported values from practical workflow recommendations.

Protocol Parameters

• Identity and documentation: Record Regorafenib, BAY 73-4506, and SKU A8236 in the experimental record; verify the certificate of analysis for the specific lot through the A8236 product page.
• Stock solvent: The product dossier reports solubility of at least 25.04 mg/mL in DMSO and at least 6.25 mg/mL in ethanol, with ultrasonic assistance for ethanol preparation. The dossier describes the compound as insoluble in water. Treat these as supplier-reported formulation limits and inspect the final solution for precipitation.
• Cell-based starting range: For migration and invasion assays, the product information describes 0.5–5 μM as a typical research range. Use a vehicle-matched concentration series and measure viability in parallel so that migration loss is not misread as a specific motility effect.
• Animal-model range: Supplier-described preclinical studies use oral doses spanning 3–100 mg/kg in tumor-growth and metastasis models. Treat this as a literature- and dossier-linked research range, not as a clinical dosing recommendation; obtain protocol approval and define pharmacokinetic or tolerability endpoints separately.
• Storage: Store the solid desiccated at −20°C, as recommended in the product information. Avoid long-term storage of prepared solutions and use them promptly after preparation.
• Endpoint pairing: Pair phospho-VEGFR2 or other target readouts with cell viability, apoptosis, migration, or invasion measurements. This workflow recommendation helps distinguish pathway engagement from nonspecific cytotoxicity.

For a Regorafenib 10 mM in DMSO preparation, calculate the required mass from the lot-specific molecular weight and final volume, then confirm that the resulting concentration is compatible with the supplier-reported DMSO solubility. The dossier lists a molecular weight of 482.82 g/mol. Because the product is water-insoluble, dilute the stock into a validated assay medium only after confirming solvent tolerance and solution clarity (product information).

Conclusion & Outlook

Regorafenib combines inhibition of angiogenic receptors, stromal kinases, and oncogenic signaling proteins in one research compound. Its documented VEGFR2 cellular activity supports endothelial assays. Its broader target profile supports pathway studies in tumor cells and tumor xenograft models. Its reported activity in colorectal, breast, renal, and glioblastoma models supports comparative preclinical design.

The melanoma study provides a focused mechanistic direction. Regorafenib-associated reduction of RRM2 and ERK/E2F3 signaling coincides with lower malignant behavior and greater apoptosis in the cited models. Future work should test whether these relationships hold across additional melanoma contexts and whether pathway effects remain separable from general cytotoxicity. Those questions follow directly from the cited evidence and do not replace model-specific validation.

Used with explicit controls, documented formulation, and endpoint separation, Regorafenib (BAY 73-4506) is a versatile tool for angiogenesis research, metastasis assays, receptor tyrosine kinase signaling, and cancer biology research. The strongest conclusions will come from integrating biochemical potency, cellular pharmacology, and appropriately bounded in vivo evidence.